Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South Africa and Uganda

• Published in: BMJ open Vol. 9; no. 2; p. e025469
• Main Authors: Stevenson, Anne, Akena, Dickens, Stroud, Rocky E, Atwoli, Lukoye, Campbell, Megan M, Chibnik, Lori B, Kwobah, Edith, Kariuki, Symon M, Martin, Alicia R, de Menil, Victoria, Newton, Charles R J C, Sibeko, Goodman, Stein, Dan J, Teferra, Solomon, Zingela, Zukiswa, Koenen, Karestan C
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.02.2019; BMJ Publishing Group
• Subjects: Bipolar disorder; Bipolar Disorder - genetics; Case-Control Studies; Consortia; Deoxyribonucleic acid; DNA; Environmental risk; Ethiopia; Genetic Predisposition to Disease; Genetics; Genetics and Genomics; Genome-Wide Association Study; Genomes; Hospitals; Humans; Kenya; Mental disorders; Mental health; Phenotype; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Psychosis; Research Design; Schizophrenia; Schizophrenia - genetics; South Africa; Uganda; South Africa; Uganda; Kenya; Ethiopia; Africa; mental Health; genetics; Africa
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2018-025469

IntroductionSchizophrenia and bipolar disorder account for a large proportion of the global burden of disease. Despite their enormous impact, little is known about their pathophysiology. Given the high heritability of schizophrenia and bipolar disorder, unbiased genetic studies offer the opportunity to gain insight into their neurobiology. However, advances in understanding the genetic architecture of schizophrenia and bipolar disorder have been based almost exclusively on subjects of Northern European ancestry. The Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis) project aims to expand our understanding of the causes of schizophrenia and bipolar disorder through large-scale sample collection and analyses in understudied African populations.Methods and analysisNeuroGAP-Psychosis is a case-control study of 34 000 participants recruited across multiple sites within Ethiopia, Kenya, South Africa and Uganda. Participants will include individuals who are at least 18 years old with a clinical diagnosis of schizophrenia or bipolar disorder (‘psychosis’) or those with no history of psychosis. Research assistants will collect phenotype data and saliva for DNA extraction. Data on mental disorders, history of physical health problems, substance use and history of past traumatic events will be collected from all participants.DNA extraction will take place in-country, with genotyping performed at the Broad Institute. The primary analyses will include identifying major groups of participants with similar ancestry using the computation-efficient programme single nucleotide polymorphisms (SNP) weights. This will be followed by a GWAS within and across ancestry groups.Ethics and disseminationAll participants will be assessed for capacity to consent using the University of California, San Diego Brief Assessment of Capacity to Consent. Those demonstrating capacity to consent will be required to provide informed consent. Ethical clearances to conduct this study have been obtained from all participating sites. Findings from this study will be disseminated in publications and shared with controlled access public databases, such as the database of Genotypes and Phenotypes, dbGaP.